Intuitive Surgical Shareholders Just Need to Relaxhttp://www.fool.com/investing/general/2013/03/01/intuitive-surgical-shareholders-just-need-to-relax.aspx Sean Williams
March 1, 2013
Companies may be innocent until proven guilty, but Intuitive Surgical (NASDAQ: ISRG) shareholders will have none of it as they took the stock to the ringer in the final minutes of trading yesterday after a federal probe into the safety of its da Vinci robotic surgical systems was disclosed.
I have to admit that, even though I have no financial interest in Intuitive Surgical, it irks the heck out of me that Citron Research might in any way, form, or shape, be correct about Intuitive Surgical. If you recall, Citron Research, a noted short-seller, released a report in December that outlined five bullet points (link opens PDF) why Intuitive Surgical could be headed lower. Specifically, those bullet points all tied back to the fact that Intuitive Surgical did a poor job disclosing the risks associated with its robots, that it failed to show substantial evidence that its robots improved the quality of surgeries performed, and that it failed to adequately train physicians to perform these procedures.
Up until now, Intuitive Surgical's quarterly results had done all of the talking. In its most recent quarter, Intuitive silenced Citron by recording a 23% increase in revenue to $609 million with systems revenue jumping 18% to $265 million as it sold 175 da Vinci surgical systems. That will, in the meantime, be put on the back burner as U.S. regulators probe the adverse event profile of its robotic system.
Make no mistake about it; I understand that this probe isn't a good thing. As I've noted previously, probes by U.S. regulators can lead to hefty fines as in the case of Johnson & Johnson (NYSE: JNJ), which paid $2.2 billion in settlements for its role in how it marketed anti-psychotic drug Risperdal, as well as two other drugs. Still, numerous other probes end with either inconclusive findings or a slap on the wrist. ABIOMED just last week (NASDAQ: ABMD) had U.S. regulators drop a 20-month investigation into the marketing of its blood-pumping device, the Impella Recover LP 2.5. Financial penalties really are a last resort unless gross negligence on the company's part is demonstrated.
Another factor worth considering is that while U.S. regulators are more closely examining the adverse events reported by physicians, they have to understand that as a percentage of patients being treated, the number of adverse event incidences has remain stable. As Intuitive Surgical sells more da Vinci systems and the number of procedures increases, it would be logical to expect the probability of adverse events to rise a bit.
Studies also exist that demonstrate that the da Vinci surgi